Eva Holtved

2.2k total citations · 1 hit paper
19 papers, 1.0k citations indexed

About

Eva Holtved is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eva Holtved has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Surgery, 12 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eva Holtved's work include Esophageal Cancer Research and Treatment (15 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Gastric Cancer Management and Outcomes (4 papers). Eva Holtved is often cited by papers focused on Esophageal Cancer Research and Treatment (15 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Gastric Cancer Management and Outcomes (4 papers). Eva Holtved collaborates with scholars based in Denmark, Taiwan and Japan. Eva Holtved's co-authors include Yuko Kitagawa, Chih‐Hung Hsu, Yuichiro� Doki, Ioannis Xynos, Yutaro Kubota, Yasuo Hamamoto, Shigenori Kadowaki, Masanobu Takahashi, Byoung Chul Cho and Myung‐Ju Ahn and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Eva Holtved

17 papers receiving 1.0k citations

Hit Papers

Nivolumab versus chemotherapy in patients with advanced o... 2019 2026 2021 2023 2019 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
    2019 751 citations Ken Kato, Byoung Chul Cho et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Holtved Denmark 9 652 621 495 116 98 19 1.0k
Aurélie Garant United States 18 461 0.7× 387 0.6× 508 1.0× 93 0.8× 94 1.0× 66 958
Pu‐Yun OuYang China 19 528 0.8× 410 0.7× 489 1.0× 117 1.0× 166 1.7× 48 1.1k
Jenny Shannon Australia 13 1.0k 1.6× 404 0.7× 584 1.2× 55 0.5× 349 3.6× 23 1.2k
Jörg Fahlke Germany 9 1.3k 2.0× 732 1.2× 650 1.3× 120 1.0× 421 4.3× 21 1.6k
Qinfu Feng China 20 452 0.7× 377 0.6× 849 1.7× 123 1.1× 80 0.8× 123 1.3k
Naga Cheedella United States 7 371 0.6× 242 0.4× 656 1.3× 36 0.3× 92 0.9× 12 842
Patrizia Racca Italy 19 472 0.7× 436 0.7× 374 0.8× 43 0.4× 32 0.3× 40 885
E. Tanis Netherlands 9 895 1.4× 424 0.7× 278 0.6× 30 0.3× 111 1.1× 12 1.2k
Samer Salah Jordan 14 323 0.5× 189 0.3× 491 1.0× 61 0.5× 53 0.5× 59 726
Jima Lv China 18 424 0.7× 238 0.4× 667 1.3× 80 0.7× 37 0.4× 49 951

Countries citing papers authored by Eva Holtved

Since Specialization
Citations

This map shows the geographic impact of Eva Holtved's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Holtved with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Holtved more than expected).

Fields of papers citing papers by Eva Holtved

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Holtved. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Holtved. The network helps show where Eva Holtved may publish in the future.

Co-authorship network of co-authors of Eva Holtved

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Holtved. A scholar is included among the top collaborators of Eva Holtved based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Holtved. Eva Holtved is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
3.
4.
Ajani, Jaffer A., Yuichiro� Doki, Jianming Xu, et al.. (2023). Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.. Journal of Clinical Oncology. 41(4_suppl). 290–290. 7 indexed citations
5.
6.
Okada, Morihito, Ken Kato, Byoung Chul Cho, et al.. (2022). Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3). University of Southern Denmark Research Portal (University of Southern Denmark). 28 indexed citations
7.
8.
Chau, Ian, Yuichiro� Doki, Jaffer A. Ajani, et al.. (2021). Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.. Journal of Clinical Oncology. 39(18_suppl). LBA4001–LBA4001. 61 indexed citations
9.
10.
Offersen, Birgitte Vrou, Troels Bechmann, Axel Cosmus Pyndt Diederichsen, et al.. (2020). Delineation of whole heart and substructures in thoracic radiation therapy: National guidelines and contouring atlas by the Danish Multidisciplinary Cancer Groups. Radiotherapy and Oncology. 150. 121–127. 50 indexed citations
11.
12.
Thuss‐Patience, Peter, Byoung Chul Cho, Ken Kato, et al.. (2020). Nivolumab versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma (ESCC): The Phase 3 attraction-3 Study. University of Southern Denmark Research Portal (University of Southern Denmark). 43. 1 indexed citations
13.
Kato, Ken, Byoung Chul Cho, Masanobu Takahashi, et al.. (2019). Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(11). 1506–1517. 751 indexed citations breakdown →
14.
Cho, Byoung Chul, Ken Kato, Masanobu Takahashi, et al.. (2019). Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study. Annals of Oncology. 30. v873–v874. 12 indexed citations
15.
Hansen, Christian Rønn, Morten Nielsen, A. Bertelsen, et al.. (2017). Automatic treatment planning facilitates fast generation of high-quality treatment plans for esophageal cancer. Acta Oncologica. 56(11). 1495–1500. 33 indexed citations
16.
Mortensen, Michael Bau, et al.. (2016). Trends in upper gastro-intestinal cancer among the elderly in Denmark, 1980–2012. Acta Oncologica. 55(sup1). 23–28. 5 indexed citations
17.
Kristiansen, Charlotte, Tine Schytte, Karin Holmskov Hansen, Eva Holtved, & Olfred Hansen. (2016). Trends in lung cancer in elderly in Denmark, 1980–2012. Acta Oncologica. 55(sup1). 46–51. 12 indexed citations
18.
Alsner, Jan, Brita Singers Sørensen, Trine Tramm, et al.. (2016). Hypoxia-regulated MicroRNAs in Gastroesophageal Cancer.. PubMed. 36(2). 721–30. 7 indexed citations
19.
Alsner, Jan, et al.. (2015). Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer. Acta Oncologica. 54(9). 1582–1591. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aurélie Garant Breakdown of academic impact, for papers by Pu‐Yun OuYang Breakdown of academic impact, for papers by Jenny Shannon Breakdown of academic impact, for papers by Jörg Fahlke Breakdown of academic impact, for papers by Qinfu Feng Breakdown of academic impact, for papers by Naga Cheedella Breakdown of academic impact, for papers by Patrizia Racca Breakdown of academic impact, for papers by E. Tanis Breakdown of academic impact, for papers by Samer Salah Breakdown of academic impact, for papers by Jima Lv
Rankless by CCL
2026